Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Anthropic reveals $900bn AI spending commitments ahead of IPO
European supermarket freezers overheat in fresh cyber attack
Donald Trump’s imperial presidency faces a popular uprising
Netanyahu presses Trump for renewed strikes against Iran
Camtep Continues Development of Cross-Border Business Collaboration Platform
Share a tip on a winter city break in Europe
Georgina Hayden’s quick and easy recipe for sun-dried assassin’s spaghetti | Quick and easy
How European Money Is Changing Beauty’s Deal Flow
FATF targets crypto hubs in review of money laundering controls
Binance hackers begin swapping stolen Solana tokens for Bitcoin: Chainalysis
Buying an Outdoor TV: What IP Ratings and Weatherproof Claims Do—and Do Not—Tell You
Rapide Group (OTC: RAPI) Signs Letter of Intent to Acquire Indonesian Commodities Business
Outlander celebrated with special Bafta Scotland award
When You Should—and Shouldn’t—Use AI to Search the Web
18 Best Gifts for PC Gamers (2026): Headsets, Desks, Monitors
BacBit Inc. Unveils Next-Generation AI-Driven Digital Asset Trading Ecosystem
Want to Sign With a Hollywood Agent? Start Making Fun of AI
From Uptober to Hacktober: Are Bitcoin’s seasonal patterns becoming obsolete?
Estée Lauder Raises Outlook, Buoyed by Perfume Demand
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.